Q-omics provides the consensus-scored PCDHGB5 profile across patient tissues and cancer cell-line models. PCDHGB5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, PCDHGB5 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PCDHGB5 RNA expression shows 17,221 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUSC, KIRC, and THYM as cancer lineages where PCDHGB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHGB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHGB5 survival associations across molecular data types. PCDHGB5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHGB5 RNA expression–survival associations across cancer types. High PCDHGB5 expression shows unfavorable associations in LUSC, CESC, BLCA and STAD, but favorable associations in KIRC and UCS. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for PCDHGB5 RNA expression.
This table summarizes PCDHGB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PCDHGB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHGB5 shows lower tumor expression in KIRC, UCEC, LUSC, COAD, STAD and BRCA. The KIRC box plot shows higher PCDHGB5 RNA expression in normal versus tumor tissue (log2 FC = −1.479, t-test p < 0.001).
This table shows molecular features associated with PCDHGB5 in patient tissues and cancer cell lines. In patient samples, PCDHGB5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHGB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and NCI60_ALL.
